← Leaderboards
Moonsoo M. Jin
Cornell University
$6,779,422
Attributed
$11,895,359
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2008–24$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$11,895,359 · 7
By mechanism
R01$10,415,345 · 4
R21$1,480,014 · 3
Top collaborators
- Harold G Craighead5 shared
- John T Lis5 shared
- Yi Wang5 shared
- Rasa Zarnegar5 shared
- Thomas J Fahey3 shared
- Koen Walter Van Besien3 shared
- Roisin M Owens1 shared
- Yanping Yang1 shared
Most similar at Cornell University
Same institution · by research overlap
- John T Lis$34,009,505
- Harold G Craighead$9,473,451
- Roisin M Owens$99,375
- Moonsoo Jin$5,813
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsEngineeringIntercellular Adhesion Molecule 1Malignant NeoplasmsDesignSiteToxic EffectBaseSpatiotemporalTumorAffinitySurfaceEvaluationValidationTechnologyDetectionVariantClinicIn VivoDoseProtocols DocumentationProteinsPublic Health RelevanceRefractory
Grant awards (25)
CAR T Cells for Advanced Thyroid Cancer$588,696
R01 · FY2024 · CA · contact PI
Enhancing CAR-T cell therapy through theranostic targeted radionuclide therapy$415,260
R21 · FY2024 · CA
CAR T Cells for Advanced Thyroid Cancer$661,659
R01 · FY2023 · CA · contact PI
CAR T Cells for Advanced Thyroid Cancer$661,926
R01 · FY2022 · CA · contact PI
Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen$517,929
R01 · FY2022 · CA · contact PI
CAR T Cells for Advanced Thyroid Cancer$693,091
R01 · FY2021 · CA · contact PI
Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen$528,498
R01 · FY2021 · CA · contact PI
Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen$528,498
R01 · FY2020 · CA · contact PI
Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen$512,642
R01 · FY2019 · CA · contact PI
Imaging-guided fine tuning of CAR T cell affinity to limit T cell cytotoxicity to tumor antigen$525,684
R01 · FY2018 · CA · contact PI
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer$351,713
R01 · FY2017 · CA · contact PI
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer$351,713
R01 · FY2016 · CA · contact PI
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer$351,713
R01 · FY2015 · CA · contact PI
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer$341,162
R01 · FY2014 · CA · contact PI
Strategy for global, unbiased mining and discovery of human monoclonal antibodies$254,250
R21 · FY2014 · AI · contact PI
Development of High Throughput Aptamer-based Protein Capture/Detection Assays tow$648,054
R01 · FY2013 · GM
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer$351,713
R01 · FY2013 · CA · contact PI
Strategy for global, unbiased mining and discovery of human monoclonal antibodies$195,630
R21 · FY2013 · AI · contact PI
Development of High Throughput Aptamer-based Protein Capture/Detection Assays tow$689,203
R01 · FY2012 · GM
Development of High Throughput Aptamer-based Protein Capture/Detection Assays tow$685,530
R01 · FY2011 · GM
Development of High Throughput Aptamer-based Protein Capture/Detection Assays tow$710,801
R01 · FY2010 · GM
Developing ICAM-1 for rhinovirus therapeutics$177,624
R21 · FY2010 · AI · contact PI
Development of High Throughput Aptamer-based Protein Capture/Detection Assays tow$715,120
R01 · FY2009 · GM
Developing ICAM-1 for rhinovirus therapeutics$238,500
R21 · FY2009 · AI · contact PI
Developing ICAM-1 for rhinovirus therapeutics$198,750
R21 · FY2008 · AI · contact PI